Airway inflammatory profile is correlated with symptoms in stable COPD: A longitudinal proof-of-concept cohort study

Marco Contoli, Simonetta Baraldo, Valentina Conti, Giulia Gnesini, Brunilda Marku, Paolo Casolari, Paola Scrigner, Paolo Morelli, Marina Saetta, Antonio Spanevello, Alberto Papi, Marco Contoli, Simonetta Baraldo, Valentina Conti, Giulia Gnesini, Brunilda Marku, Paolo Casolari, Paola Scrigner, Paolo Morelli, Marina Saetta, Antonio Spanevello, Alberto Papi

Abstract

Background and objective: Symptoms negatively impact the quality of life and long-term prognosis of patients with chronic obstructive pulmonary disease (COPD). Little is known about the relationship linking airway inflammation and symptoms in stable COPD. In this study, we evaluated whether respiratory symptoms in COPD are related to sputum inflammatory cellular profile and whether symptom changes are associated with changes in airway inflammation.

Methods: A total of 40 patients with stable COPD with moderate-to-severe airflow obstruction were enrolled. Patients were visited weekly over 4 weeks. At each visit, patients underwent clinical assessments, lung function tests and sputum induction. Patients recorded daily dyspnoea, sputum and cough scores.

Results: The changes between two consecutive visits in the percent of sputum neutrophils and eosinophils were related to the changes in the cough (P < 0.001; r = 0.63) and dyspnoea scores (P < 0.001; r = 0.58) of the prior week. Furthermore, using regression analyses, we were able to demonstrate that changes in the cough score were specifically associated to the change in neutrophils, while changes in the dyspnoea score and use of rescue medications were associated with changes in eosinophils numbers.

Conclusion: Our study showed an association between symptoms and the sputum inflammatory profile. In particular, changes in symptoms (cough and dyspnoea) were correlated with changes in the specific sputum inflammatory cell components of airway inflammation (neutrophils and eosinophils, respectively), providing novel information on the mechanisms of disease manifestation.

Trial registration: ClinicalTrials.gov NCT01216592.

Keywords: chronic obstructive pulmonary disease; eosinophils; inflammation; neutrophils; symptoms.

© 2019 Asian Pacific Society of Respirology.

References

REFERENCES

    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease [Updated 2017.] Available from URL:
    1. Mannino DM, Doherty DE, Sonia Buist A. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir. Med. 2006; 100: 115-22.
    1. Figarska SM, Boezen HM, Vonk JM. Dyspnea severity, changes in dyspnea status and mortality in the general population: the Vlagtwedde/Vlaardingen study. Eur. J. Epidemiol. 2012; 27: 867-76.
    1. Lahousse L, Seys LJM, Joos GF, Franco OH, Stricker BH, Brusselle GG. Epidemiology and impact of chronic bronchitis in chronic obstructive pulmonary disease. Eur. Respir. J. 2017; 50: pii: 1602470.
    1. Kessler R, Partridge MR, Miravitlles M, Cazzola M, Vogelmeier C, Leynaud D, Ostinelli J. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur. Respir. J. 2011; 37: 264-72.
    1. Laviolette L, Laveneziana P, ERS Research Seminar Faculty. Dyspnoea: a multidimensional and multidisciplinary approach. Eur. Respir. J. 2014; 43: 1750-62.
    1. Hogg J, Chu F, Utokaparch S, Woods R, Elliott W, Buzatu L, Cherniack R, Rogers R, Sciurba F, Coxson H et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350: 2645-53.
    1. Saetta M, Baraldo S, Corbino L, Turato G, Braccioni F, Rea F, Cavallesco G, Tropeano G, Mapp CE, Maestrelli P et al. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 160: 711-7.
    1. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, McCormick M, Haldar K, Kebadze T, Duvoix A et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am. J. Respir. Crit. Care Med. 2011; 184: 662-71.
    1. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000; 55: 114-20.
    1. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr. Med. Res. Opin. 2009; 25: 2043-8.
    1. Mallia P, Message SD, Gielen V, Contoli M, Grey K, Kebadze T, Aniscenko J, Laza-Stanca V, Edwards MR, Slater L et al. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am. J. Respir. Crit. Care Med. 2011; 183: 734-42.
    1. Contoli M, Pauletti A, Rossi MR, Spanevello A, Casolari P, Marcellini A, Forini G, Gnesini G, Marku B, Barnes N et al. Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD. Eur. Respir. J. 2017; 50: 1700451.
    1. Stănescu D, Sanna A, Veriter C, Kostianev S, Calcagni PG, Fabbri LM, Maestrelli P. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax 1996; 51: 267-71.
    1. Zhao P, Lieu T, Barlow N, Sostegni S, Haerteis S, Korbmacher C, Liedtke W, Jimenez-Vargas NN, Vanner SJ, Bunnett NW. Neutrophil elastase activates protease-activated receptor-2 (PAR2) and transient receptor potential vanilloid 4 (TRPV4) to cause inflammation and pain. J. Biol. Chem. 2015; 290: 13875-87.
    1. Saetta M, Turato G, Facchini FM, Corbino L, Lucchini RE, Casoni G, Maestrelli P, Mapp CE, Ciaccia A, Fabbri LM. Inflammatory cells in the bronchial glands of smokers with chronic bronchitis. Am. J. Respir. Crit. Care Med. 1997; 156: 1633-9.
    1. O'Donnell RA, Peebles C, Ward JA, Daraker A, Angco G, Broberg P, Pierrou S, Lund J, Holgate ST, Davies DE et al. Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD. Thorax 2004; 59: 837-42.
    1. Peleman RA, Rytilä PH, Kips JC, Joos GF, Pauwels RA. The cellular composition of induced sputum in chronic obstructive pulmonary disease. Eur. Respir. J. 1999; 13: 839-43.
    1. Donaldson GC, Seemungal TAR, Patel IS, Bhowmik A, Wilkinson TMA, Hurst JR, Maccallum PK, Wedzicha JA. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005; 128: 1995-2004.
    1. Contoli M, Baraldo S, Marku B, Casolari P, Marwick JA, Turato G, Romagnoli M, Caramori G, Saetta M, Fabbri LM et al. Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up. J. Allergy Clin. Immunol. 2010; 125: 830-7.
    1. Rabe KF, Beghe B, Fabbri LM. Peripheral eosinophil count as a biomarker for the management of COPD: not there yet. Eur. Respir. J. 2017; 50: 1702165.
    1. Kerkhof M, Sonnappa S, Postma DS, Brusselle G, Agusti A, Anzueto A, Jones R, Papi A, Pavord I, Pizzichini E et al. Blood eosinophil count and exacerbation risk in patients with COPD. Eur. Respir. J. 2017; 50: pii: 1700761.
    1. Turato G, Semenzato U, Bazzan E, Biondini D, Tinè M, Torrecilla N, Forner M, Marin JM, Cosio MG, Saetta M. Blood eosinophilia does not reflect tissue eosinophils nor worsen clinical outcomes in COPD. Am. J. Respir. Crit. Care Med. 2018; 197: 1216-9.
    1. Hastie AT, Martinez FJ, Curtis JL, Doerschuk CM, Hansel NN, Christenson S, Putcha N, Ortega VE, Li X, Barr RG et al.; SPIROMICS Investigators. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respir. Med. 2017; 5: 956-67.
    1. Song H, Yun C, Xu M, Sun D. Different expression about induced sputum cell sorting in the two main types of chronic obstructive pulmonary disease. Diagn. Cytopathol. 2017; 45: 1073-7.
    1. Evans CM, Fryer AD, Jacoby DB, Gleich GJ, Costello RW. Pretreatment with antibody to eosinophil major basic protein prevents hyperresponsiveness by protecting neuronal M2 muscarinic receptors in antigen-challenged guinea pigs. J. Clin. Invest. 1997; 100: 2254-62.
    1. Leckie MJ, Brinke ten A, Khan J, Diamant Z, O'Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356: 2144-8.
    1. Iwashita H, Morita S, Sagiya Y, Nakanishi A. Role of eosinophil chemotactic factor by T lymphocytes on airway hyperresponsiveness in a murine model of allergic asthma. Am. J. Respir. Cell Mol. Biol. 2006; 35: 103-9.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren